LUND, SE / ACCESSWIRE / October 29, 2024 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) invites investors, analysts and the press to a ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, ten ...
Therefore, Belite Bio is evaluating safety and efficacy of Tinlarebant in GA patients in a 2-year Phase 3 study (PHOENIX). This press release contains forward-looking statements about future ...
Therefore, Belite Bio is evaluating safety and efficacy of Tinlarebant in GA patients in a 2-year Phase 3 study (PHOENIX). This press release contains forward-looking statements about future ...
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt Disease type 1 (STGD1) and ...
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) ("Belite” or the "Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback